{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:40:02Z","timestamp":1761514802860,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejphar.2021.174433","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T12:47:42Z","timestamp":1629204462000},"page":"174433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pharmacological characterisation of the CB1 receptor antagonist activity of cannabidiol in the rat vas deferens bioassay"],"prefix":"10.1016","volume":"909","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0431-2055","authenticated-orcid":false,"given":"Amna C.","family":"Mazeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Angus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3339-040X","authenticated-orcid":false,"given":"Christine E.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174433_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.tips.2009.12.002","article-title":"Vas deferens--a model used to establish sympathetic cotransmission","volume":"31","author":"Burnstock","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2021.174433_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fphar.2017.00269","article-title":"Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders","volume":"8","author":"Campos","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10425179509020870","article-title":"Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein","volume":"5","author":"Chakrabarti","year":"1995","journal-title":"DNA Seq"},{"key":"10.1016\/j.ejphar.2021.174433_bib4","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.bjp.0703930","article-title":"Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens","volume":"132","author":"Christopoulos","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib5","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/sj.bjp.0701301","article-title":"Inhibition by cannabinoid receptor agonists of acetylcholine release from the Guinea-pig myenteric plexus","volume":"121","author":"Coutts","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International union of pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2021.174433_bib7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics"},{"year":"2014","series-title":"A Pharmacology Primer, Techniques for More Effective and Strategic Drug Discovery","author":"Kenakin","key":"10.1016\/j.ejphar.2021.174433_bib8"},{"key":"10.1016\/j.ejphar.2021.174433_bib9","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0014-2999(00)00062-5","article-title":"Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse","volume":"391","author":"Lay","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0165-6147(00)89066-5","article-title":"Analysis of competitive agonist-antagonist interactions by nonlinear regression","volume":"16","author":"Lew","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2021.174433_bib12","doi-asserted-by":"crossref","first-page":"102588","DOI":"10.1016\/j.autneu.2019.102588","article-title":"The effects of varying Mg(2+) ion concentrations on contractions to the cotransmitters ATP and noradrenaline in the rat vas deferens","volume":"222","author":"Mazeh","year":"2019","journal-title":"Auton. Neurosci."},{"key":"10.1016\/j.ejphar.2021.174433_bib13","doi-asserted-by":"crossref","first-page":"173767","DOI":"10.1016\/j.ejphar.2020.173767","article-title":"Cannabidiol selectively inhibits the contraction of rat small resistance arteries: possible role for CGRP and voltage-gated calcium channels","volume":"891","author":"Mazeh","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","article-title":"Pharmacology of cannabinoid CB1 and CB2 receptors","volume":"74","author":"Pertwee","year":"1997","journal-title":"Pharmacol. Ther."},{"year":"2014","series-title":"Handbook of Cannabis","author":"Pertwee","key":"10.1016\/j.ejphar.2021.174433_bib16"},{"key":"10.1016\/j.ejphar.2021.174433_bib17","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/j.1476-5381.1996.tb15643.x","article-title":"Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder","volume":"118","author":"Pertwee","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib18","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1111\/j.1476-5381.1996.tb15663.x","article-title":"Further evidence for the presence of cannabinoid CB1 receptors in Guinea-pig small intestine","volume":"118","author":"Pertwee","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(02)02624-9","article-title":"(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens","volume":"456","author":"Pertwee","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib20","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/0024-3205(95)00174-5","article-title":"Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist","volume":"56","author":"Rinaldi-Carmona","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2021.174433_bib21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","article-title":"SR141716A, a potent and selective antagonist of the brain cannabinoid receptor","volume":"350","author":"Rinaldi-Carmona","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2021.174433_bib22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0022-3565(24)37266-0","article-title":"SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor","volume":"284","author":"Rinaldi-Carmona","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174433_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ntt.2014.09.003","article-title":"Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures","volume":"46","author":"Rosenthaler","year":"2014","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.ejphar.2021.174433_bib24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0165-6147(00)01805-8","article-title":"Modulation of transmitter release via presynaptic cannabinoid receptors","volume":"22","author":"Schlicker","year":"2001","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2021.174433_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.bjp.0705449","article-title":"Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release","volume":"140","author":"Schlicker","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib26","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1074\/jbc.271.12.6941","article-title":"Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A","volume":"271","author":"Shire","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2021.174433_bib27","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3390\/ani9090686","article-title":"The endocannabinoid system of animals","volume":"9","author":"Silver","year":"2019","journal-title":"Animals (Basel)"},{"key":"10.1016\/j.ejphar.2021.174433_bib28","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bph.14440","article-title":"Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors","volume":"176","author":"Tham","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174433_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejphar.2004.01.023","article-title":"6\"-Azidohex-2\"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist","volume":"487","author":"Thomas","year":"2004","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921005860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921005860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:55:31Z","timestamp":1757976931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921005860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":30,"alternative-id":["S0014299921005860"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174433","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological characterisation of the CB1 receptor antagonist activity of cannabidiol in the rat vas deferens bioassay","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174433"}}